Latest Conference Articles

No Significant Difference in EFS, OS Between Herceptin and Biosimilar, Ontruzant, at 3 Years

Kelly Davio

June 3 2019

Between patients treated with the biosimilar and those treated with the reference product who were not exposed to lots of Herceptin with lower antibody-dependent cell-mediated cytotoxicity, no difference was observed in event-free survival (EFS) or overall survival (OS).

Researchers Report on 3 Bevacizumab Biosimilar Development Programs

Kelly Davio

May 31 2019

Alongside this week’s 2019 annual meeting of the American Society of Clinical Oncology, 3 developers reported on their progress with developing biosimilars of bevacizumab.

What Can US Learn About Biosimilars From Europe?

Allison Inserro

May 24 2019

Europe has several lessons for the US biosimilar market, according to a pharmaceutical executive who spoke during ISPOR 2019.

Fresenius Kabi's Adalimumab Biosimilar Produces Comparable QOL Improvements to Humira

Kelly Davio

May 22 2019

Treatment with the biosimilar, the investigators concluded, resulted in comparable, maintained quality of life improvements that were not impacted by a switch from the reference product.

Biosimilar Monotherapy Sequence for RA Can Be Considered Cost-Effective, Study Finds

The Center for Biosimilars Staff

May 21 2019

Rheumatoid arthritis (RA) has a considerable economic burden, and costly biologics, are often restricted to cases in which patients fail to respond adequately to methotrexate or other conventional disease-modifying antirheumatic drugs, which may be difficult for some patients to tolerate.

Researchers Predict Substantial Savings for Europe on the Strength of Biosimilar Adalimumab

Kelly Davio

May 21 2019

During the ISPOR 2019 annual meeting, teams of investigators presented data estimating just how much healthcare systems could save by adopting biosimilar adalimumab for all indications of its reference in adult patients. The results highlighted both the scale of potential savings and the variability among European nations.

Health Plan Restrictions Likely to Have an Impact on Biosimilars, Orphan Drugs

Kelly Davio

May 20 2019

Despite their benefits to patients, innovative treatments, including biologics, come at a high cost to the healthcare system, and those in a position to make coverage decisions for these products must grapple with these therapies’ affordability. During the ISPOR 2019 meeting, researchers presented findings on how health plan restrictions could limit orphan drug coverage—and encourage biosimilar use—as a means to manage their budgets.

Biologics in IBD Linked With Lower Surgery Costs, Corticosteroid Use, and Opioid Use

Kelly Davio

May 19 2019

Research presented at this week’s ISPOR 2019 meeting sheds important light on the impact of biologics on the use of other healthcare resources.

Researchers Present Findings on Patient Preferences, Outcomes With G-CSFs

The Center for Biosimilars Staff

May 18 2019

During this week’s meeting of the International Society for Pharmacoeconomic and Outcomes Research, held from May 18 to 22 in New Orleans, Louisiana, researchers presented findings on both the patient attitudes toward granulocyte colony-stimulating factor (G-CSF) therapies and their effectiveness in the prophylaxis of febrile neutropenia.

Inside the UK Switch to Biosimilar Adalimumab

Kelly Davio

May 15 2019

During the Biosimilars Commercialisation Summit, held May 14-15, 2019, in Amsterdam, the Netherlands, a specialist pharmacist for a large National Health Service healthcare trust explained how the transition to biosimilars worked at a practical level in the UK home care system, and shared lessons learned from the experience.